Zobrazeno 1 - 10
of 56
pro vyhledávání: '"S. Lissandre"'
Autor:
A. Schmidt-Tanguy, R. Houot, S. Lissandre, J. F. Abgrall, P. Casassus, P. Rodon, B. Desablens, J. P. Marolleau, R. Garidi, T. Lamy, M.-P. Moles-Moreau, G. Damaj
Publikováno v:
Advances in Hematology, Vol 2014 (2014)
Background. Primary bone lymphoma (PBL) is a rare entity that has only been reviewed in one prospective and small retrospective studies, from which it is difficult to establish treatment guidelines. We prospectively evaluated high-dose or conventiona
Externí odkaz:
https://doaj.org/article/5c4641071380474bab5b7eb77a197ab7
Autor:
P. D'Halluin, B. Lioger, E. Mercier, Julie Mankikian, S. Lissandre, F. Beau Salinas, S. Marchand Adam, E. Diot
Publikováno v:
Heart & Lung. 43:120-123
Lenalidomide is an immunomodulating drug structurally similar to thalidomide. It is indicated for patients with relapsing or refractory multiple myeloma in combination with dexamethasone, and for patients with myelodysplastic syndromes associated wit
Autor:
M.-P. Moles, A. Tanguy-Schmidt, S. Lissandre, M. Hunault-Berger, M. Zidane-Marinnes, Anne Croue, Martine Avenel-Audran, M. Dib
Publikováno v:
Annales de Dermatologie et de Vénéréologie. 136:443-446
Resume Introduction Le bortezomib (Velcade ® ) est un inhibiteur selectif du proteasome. Il est indique dans le traitement de myelomes multiples refractaires ou en rechute et permet d’obtenir 35 % de reponse d’une duree mediane de 12 mois. De no
Autor:
Jean-Pierre Marolleau, T. Lamy, S Lissandre, B Desablens, Ghandi Damaj, JF Abgrall, Roch Houot, Marie-Pierre Moles-Moreau, Philippe Casassus, Reda Garidi, Aline Schmidt-Tanguy, P Rodon
Publikováno v:
Advances in Hematology
Advances in Hematology, 2014, 2014, pp.512508. ⟨10.1155/2014/512508⟩
Advances in Hematology, Hindawi, 2014, 2014, pp.512508. ⟨10.1155/2014/512508⟩
Advances in Hematology, Vol 2014 (2014)
Advances in Hematology, 2014, 2014, pp.512508. ⟨10.1155/2014/512508⟩
Advances in Hematology, Hindawi, 2014, 2014, pp.512508. ⟨10.1155/2014/512508⟩
Advances in Hematology, Vol 2014 (2014)
Background. Primary bone lymphoma (PBL) is a rare entity that has only been reviewed in one prospective and small retrospective studies, from which it is difficult to establish treatment guidelines. We prospectively evaluated high-dose or conventiona
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9012b743f3217846fc579a8cef85ead
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01155268
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01155268
Autor:
S. Lissandre, Dominique Perrotin, A. Bree, Eve Haguenoer, S. Sunder, Philippe Lanotte, Catherine Schouler, Antoine Guillon, E. Helloin, D. Bouvet
Publikováno v:
Journal of Medical Microbiology
Journal of Medical Microbiology, Society for General Microbiology, 2012, 61 (9), pp.1324-1327. ⟨10.1099/jmm.0.042366-0⟩
Journal of Medical Microbiology, Society for General Microbiology, 2012, 61 (9), pp.1324-1327. ⟨10.1099/jmm.0.042366-0⟩
International audience; Cellulitis due to Escherichia coli (E. coli) are rare and usually secondary to cutaneous portal of entry. Skin and soft tissue infection (SSTI) secondary to E. coli bacteraemia has been exclusively reported in immunodeficient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5dc2c3ffbb17ea423e2680950a5799a2
https://hal.inrae.fr/hal-02650426
https://hal.inrae.fr/hal-02650426
Autor:
Olivier Dereure, F. Aubin, E Hainaut, Gérard Socié, Marisa Battistella, Felipe Suarez, Sylvie François, J.-D. Bouaziz, Jacqueline Rivet, Aurélie Ravinet, Sylvain Garciaz, Martine Bagot, Eolia Brissot, Anne Dompmartin, Marie Beylot-Barry, M.-D. Vignon-Pennamen, S. Dalle, M. D’Incan, Henri Adamski, Pauline Brice, Groupe français d’étude des lymphomes cutanés, Saskia Ingen-Housz-Oro, Pascal Joly, Pascal Turlure, S Lissandre, Sophie Servais, A. de Masson, Remy Dulery
Publikováno v:
Annales de Dermatologie et de Vénéréologie. 140:S361-S362
Autor:
A, Tanguy-Schmidt, M, Avenel-Audran, A, Croué, S, Lissandre, M, Dib, M, Zidane-Marinnes, M-P, Moles, M, Hunault-Berger
Publikováno v:
Annales de dermatologie et de venereologie. 136(5)
Bortezomid is a potent proteasome inhibitor used in patients with relapsing or refractory multiple myeloma and provides a 35% response with a median duration of response of 12 months. Numerous adverse effects are known, mainly comprising haematologic
Autor:
D. Carmier, C. Dartigeas, Patrice Diot, S. Lissandre, C. Rousselot-Denis, Sylvain Marchand-Adam
Publikováno v:
Revue des Maladies Respiratoires. 29:A93
Autor:
C. Sebban, H. Ghesquières, N. Ifrah, Bertrand Favier, Lionel Perrier, P. Moreau, S. Lissandre, D. Perol, P. Quittet, Carole Siani, A. Lefranc, F. Jardin
Publikováno v:
Value in Health. 14:A165
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.